Next steps on the thiopurine methyltransferase 6-thioguanine nucleotide pathway

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 3, 2006, Pages 282-283

  Colletti, Richard B ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; NUCLEOTIDE; PREDNISONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DOSE RESPONSE; DRUG METABOLISM; EDITORIAL; ENZYME ACTIVITY; ERYTHROCYTE; FOOD AND DRUG ADMINISTRATION; GASTROENTEROLOGY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PEDIATRICS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AZATHIOPRINE; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; ERYTHROCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; NUCLEOTIDES; REMISSION INDUCTION; THIOGUANINE;

EID: 33748542279     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000237940.50791.70     Document Type: Editorial

References (11)

1. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047-53.
2. Banerjee S, Bishop W. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center: role of thiopurine methyl transferase and 6-mercaptopurine metabolite measurements. J Pediatr Gastroenterol Nutr 2006;43:324-30.
3. Imuran [package insert]. San Diego, CA: Prometheus Laboratories, Inc, 2005.
4. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:593-9.
5. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100:2239-47.
6. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-9.
7. IBD Guideline Team, Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for management of inflammatory bowel disease. Available at: http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev- based/ibd.htm.
8. Colletti RB, Baldassano RN, Milov DE, et al, PIBDNet - the Pediatric IBD Network for Research and Improvement. Variation in initial evaluation and treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2005;41:537.
9. Colletti RB, Baldassano RN, Milov D, et al, PIBDNet-the Pediatric IBD Network for Research and Improvement. Variation in initial 6-mercaptopurine dosage in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:536.
10. Berwick DM. Controlling variation in health care. Med Care 1991;29:1212-25.
11. Tsai AC, Morton SC, Mangione CM, et al. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care 2005;11:478-88.